
|Videos|January 4, 2018
Dr. Carvajal Discusses the Biology of Extracutaneous Melanoma
Author(s)Richard Carvajal, MD
Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, discusses the biology and distinctions of extracutaneous melanoma.
Advertisement
Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, discusses the biology and distinctions of extracutaneous melanoma.
Extracutaneous melanoma is a very distinct disease from a biological and clinical standpoint, according to Carvajal. Extracutaneous melanoma needs to be thought of as a different disease than cutaneous melanoma, Carvajal adds, since they do not respond to treatments the same way.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































